More Hong Kong residents are getting their first Covid-19 vaccinations, though the majority are receiving a Chinese immunization that studies have shown gives inadequate protection against the recently arrived omicron strain.
Among the newly vaccinated, 61% opted for a shot from Sinovac Biotech Ltd. that has been shown to be less potent against the omicron strain. The remainder received a shot from BioNTech SE that uses new mRNA technology to target the virus’s genetic makeup.
Initial studies found that three doses of the BioNTech vaccine are needed for adequate protection against omicron, while even three doses of Sinovac’s shot aren’t enough. Despite this, the Sinovac immunization is often chosen by people trying to avoid the side effects that a potent mRNA shot may carry.